- Investor's Business Daily•2 hours ago
Exelixis is teaming up with Bristol-Myers Squibb and Roche to test its Cabometyx and their immuno-oncology drugs in liver and bladder cancer.
- American City Business Journals•9 hours ago
A Delaware-based biopharmaceutical company is headed to the S&P 500, a change that will become effective at the start of trading on Tuesday. Incyte (INCY) will replace Spectra Energy Corp. (SE) on the biotechnology sub-industry index . The announced shift came a day after the Wilmington biopharma firm and University of Pennsylvania announced a new research alliance that will focus on assessing new cancer treatments under development and advancing immunotherapy to fight cancer.
- Zacks•12 hours ago
In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.
INCY : Summary for Incyte Corporation - Yahoo Finance
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||133.65 x 200|
|Ask||133.98 x 300|
|Day's Range||130.25 - 134.96|
|52 Week Range||60.30 - 134.96|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||248.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|